Indeed, prevalent diabetes can vary in duration, exposure to glucose-lowering medications (including insulin), and complications, making it difficult to determine the role of hyperglycemia or insulin resistance per se in lung cancer development. The gene discussed is INS; the disease is diabetes mellitus.